JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE

Objective: In the 5-year follow-up of patients diagnosed with Juvenile Myelomonocytic Leukemia (JMML) in a single center; reveal treatment and survival analyzes Methodology: In this study, clinical and laboratory data of 12 JMML patients followed in Ankara Pediatric Hematology Hospital and Ankara Ci...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yunus Murat Akcabelen, Dilek Kaçar, Ayça Koca Yozgat, Özlem Arman Bilir, Dilek Gürlek Gökçebay, Turan Bayhan, İkbal Ok Bozkaya, Namık Yaşar Özbek, Neşe Yaralı
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/a72aeab0c8db4fee96fe6f0fc022886b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a72aeab0c8db4fee96fe6f0fc022886b
record_format	dspace
spelling	oai:doaj.org-article:a72aeab0c8db4fee96fe6f0fc022886b2021-11-10T04:33:32ZJUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE2531-137910.1016/j.htct.2021.10.993https://doaj.org/article/a72aeab0c8db4fee96fe6f0fc022886b2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011408https://doaj.org/toc/2531-1379Objective: In the 5-year follow-up of patients diagnosed with Juvenile Myelomonocytic Leukemia (JMML) in a single center; reveal treatment and survival analyzes Methodology: In this study, clinical and laboratory data of 12 JMML patients followed in Ankara Pediatric Hematology Hospital and Ankara City Hospital Pediatric Hematology Clinics between 2015-2020 were analyzed retrospectively. Results: The median age at diagnosis was 1.7 years (0.23-5.7). Monosomy 7, 4 PTPN11, 2 NRAS, 4 KRAS, 1 CBL mutations were detected in 2 of the patients. Hematopoietic stem cell transplantation was performed in 8 of the patients. Before transplantation, 7 patients had received a median of 4 cycles of azacitidine treatment. The mean time from diagnosis to transplantation was 15 months (1-29 months). The 5-year overall survival at median 15-month follow-up was 50%. Conclusion: With hypomethylating agents and HSCT, survival in JMML improves compared to historical control groups. However, further multicenter prospective studies are needed to prevent long-term mortality and morbidity.Yunus Murat AkcabelenDilek KaçarAyça Koca YozgatÖzlem Arman BilirDilek Gürlek GökçebayTuran Bayhanİkbal Ok BozkayaNamık Yaşar ÖzbekNeşe YaralıElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S25- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Yunus Murat Akcabelen Dilek Kaçar Ayça Koca Yozgat Özlem Arman Bilir Dilek Gürlek Gökçebay Turan Bayhan İkbal Ok Bozkaya Namık Yaşar Özbek Neşe Yaralı JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
description	Objective: In the 5-year follow-up of patients diagnosed with Juvenile Myelomonocytic Leukemia (JMML) in a single center; reveal treatment and survival analyzes Methodology: In this study, clinical and laboratory data of 12 JMML patients followed in Ankara Pediatric Hematology Hospital and Ankara City Hospital Pediatric Hematology Clinics between 2015-2020 were analyzed retrospectively. Results: The median age at diagnosis was 1.7 years (0.23-5.7). Monosomy 7, 4 PTPN11, 2 NRAS, 4 KRAS, 1 CBL mutations were detected in 2 of the patients. Hematopoietic stem cell transplantation was performed in 8 of the patients. Before transplantation, 7 patients had received a median of 4 cycles of azacitidine treatment. The mean time from diagnosis to transplantation was 15 months (1-29 months). The 5-year overall survival at median 15-month follow-up was 50%. Conclusion: With hypomethylating agents and HSCT, survival in JMML improves compared to historical control groups. However, further multicenter prospective studies are needed to prevent long-term mortality and morbidity.
format	article
author	Yunus Murat Akcabelen Dilek Kaçar Ayça Koca Yozgat Özlem Arman Bilir Dilek Gürlek Gökçebay Turan Bayhan İkbal Ok Bozkaya Namık Yaşar Özbek Neşe Yaralı
author_facet	Yunus Murat Akcabelen Dilek Kaçar Ayça Koca Yozgat Özlem Arman Bilir Dilek Gürlek Gökçebay Turan Bayhan İkbal Ok Bozkaya Namık Yaşar Özbek Neşe Yaralı
author_sort	Yunus Murat Akcabelen
title	JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
title_short	JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
title_full	JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
title_fullStr	JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
title_full_unstemmed	JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
title_sort	juvenile myelomonocytic leukemia single center experience
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/a72aeab0c8db4fee96fe6f0fc022886b
work_keys_str_mv	AT yunusmuratakcabelen juvenilemyelomonocyticleukemiasinglecenterexperience AT dilekkacar juvenilemyelomonocyticleukemiasinglecenterexperience AT aycakocayozgat juvenilemyelomonocyticleukemiasinglecenterexperience AT ozlemarmanbilir juvenilemyelomonocyticleukemiasinglecenterexperience AT dilekgurlekgokcebay juvenilemyelomonocyticleukemiasinglecenterexperience AT turanbayhan juvenilemyelomonocyticleukemiasinglecenterexperience AT ikbalokbozkaya juvenilemyelomonocyticleukemiasinglecenterexperience AT namıkyasarozbek juvenilemyelomonocyticleukemiasinglecenterexperience AT neseyaralı juvenilemyelomonocyticleukemiasinglecenterexperience
_version_	1718440683041193984

JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE

Ejemplares similares